Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections

Sponsor
Ain Shams University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05077592
Collaborator
(none)
760
1
2
4
189.6

Study Details

Study Description

Brief Summary

A Randomized controlled trail to To assess the efficacy of povidone-iodine wash before wound closure in preventing surgical site infections.

Condition or Disease Intervention/Treatment Phase
  • Drug: 10% Povidone Iodine
Phase 4

Detailed Description

Surgical site infections are post-operative infections of the incision or organ or space that was included in the surgical field. Incisional surgical site infections (SSIs) are a growing healthcare challenge.

Currently, up to 10% of surgical procedures may be complicated by an SSI [3]. Not only do SSIs lead to worse patient outcomes, but they also account for a large proportion of healthcare expenditure.

In the United Kingdom alone, SSIs are estimated to cost the National Health Service 1 billion pounds annually.

The problem is further compounded in low- and middle-income countries (LMICs) where the prevalence of antibiotic-resistant infections is increasing, and national healthcare budgets are strained.

In fact, SSIs are estimated to account for additional costs of up to $30,000 in LMICs.

The global crisis of drug-resistant bacteria has further highlighted the need for more effective perioperative preventive strategies to minimize healthcare-associated resistant infections.

Optimal surgical antisepsis is critical in reducing the incidence of SSIs, and therefore in reducing the use of postoperative antibiotics.

Recently, there has been a renewed interest in using povidone-iodine (PVI) intraoperative wound irrigation to achieve this goal. The choice of PVI is especially suitable for LMICs where the availability of chlorhexidine preparations may be limited by scarce resources.

A possible adjunctive role of pre-wound closure PVI irrigation in reducing incisional SSIs is still unclear.

A meta-analysis by López-Cano et al. analyzed data of 7,601 patients and found a reduction in overall SSI rate. However, the heterogeneity and uncertain quality of most studies limited the synthesis of conclusive evidence.

The possible benefits of irrigating the surface of an open incision include local antimicrobial effect, physical removal of debris and dilution of contamination. Recent guidelines have all emphasized the lack of sufficient evidence on intraoperative use of PVI.

The investigators aim to conduct a randomized controlled trial in Ain Shams University Hospitals to compare the effect of adding PVI wash prior to skin closure to direct wound closure on reducing the rates of SSIs.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
760 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
A statistician not directly involved in the study or analysis will prepare a computer-generated randomization sequence. No blocking will be used. The sequence will be provided to the trialists in the form of serially numbered opaque envelopes containing details of either the intervention or the control and a random identifier.
Primary Purpose:
Prevention
Official Title:
Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections: A Randomized Controlled Trial
Actual Study Start Date :
Sep 18, 2021
Anticipated Primary Completion Date :
Dec 18, 2021
Anticipated Study Completion Date :
Jan 18, 2022

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

Direct Wound closure

Active Comparator: Intervention

The use of 10% surgical povidone iodine to wash the wound directly after fascial closure and before wound closure

Drug: 10% Povidone Iodine
Povidone-iodine is a topical antiseptic agent used for the treatment and prevention of infection in wounds.
Other Names:
  • betadine
  • Outcome Measures

    Primary Outcome Measures

    1. Surgical Site Infection Incidence [30 days]

      Using the CDC Checklist for Superficial and deep Surgical site infection.

    Secondary Outcome Measures

    1. Post-operative morbidity and mortality [30 Days]

      Using the Clavien-Dindo classification system

    2. Length of hospital stay [30 Days]

      in days using the hospital records

    3. Readmission and reoperations related to Surgical site infection [30 Days]

      Using the hospital records, Number of reoperations and readmissions due to surgical site infection.

    4. Infectious complications [30 Days]

      Using qSOFA and SOFA score. such as Sepsis, septic shock, multiple-organ dysfunction syndrome, wound dehiscence

    5. Microbiology culture and sensitivity results [30 Days]

      A microbiology report that contains the exact pathogen strain and antibiotic sensitivity report.

    6. Local adverse events for povidone-iodine application [30 Days]

      Symptoms and sings

    7. Cost analysis [30 Days]

      In terms of extra hospital stay days and readmission days costs.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Adult patients (≥ 18 years old)

    • Open and minimally invasive surgeries

    • Emergency (any unplanned admission) and elective (planned admission) surgical procedures

    • Clean, Clean-Contaminated, Contaminated, Dirty wounds

    • Inclusion surgery list according to Current Procedural Terminology (CPT) National Healthcare Safety Network (NHSN) operative procedure code mapping

    Exclusion Criteria:
    • Povidone-iodine allergy

    • Surgeries for infected wounds.

    • Exclusion surgery list according to Current Procedural Terminology (CPT) National Healthcare Safety Network (NHSN) operative procedure code mapping.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ain Shams University Hospital Cairo Egypt 11591

    Sponsors and Collaborators

    • Ain Shams University

    Investigators

    • Principal Investigator: Waleed AbdelGhany, Professor, Ain Shams University

    Study Documents (Full-Text)

    More Information

    Publications

    None provided.
    Responsible Party:
    Walid Ahmed Abdel-Ghany, Professor, Ain Shams University
    ClinicalTrials.gov Identifier:
    NCT05077592
    Other Study ID Numbers:
    • POV-2021
    First Posted:
    Oct 14, 2021
    Last Update Posted:
    Oct 14, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 14, 2021